References
- Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005; 7: 134-53. doi: 10.1215/S1152851704001115
- Mesti T, Ocvirk J. Malignant gliomas: old and new systemic treatment approaches. Radiol Oncol 2016; 50: 129-38. doi: 10.1515/raon-2015-0003
- Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 2012; 18: 5562-71. doi: 10.1158/1078-0432.CCR-12-1773
- Losman JA, Kaelin WG, Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 2013; 27: 836-52. doi: 10.1101/gad.217406.113
- Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44. doi: 10.1038/nature08617
- Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-67. doi: 10.1016/j.ccr.2010.11.015
- Duarte IF, Marques J, Ladeirinha AF, Rocha C, Lamego I, Calheiros R, et al. Analytical approaches toward successful human cell metabolome studies by NMR spectroscopy. Anal Chem 2009; 81: 5023-32. doi: 10.1021/ac900545q
- Cuperlovic-Culf M, Barnett DA, Culf AS, Chute I. Cell culture metabolomics: applications and future directions. Drug Discov Today 2010; 15: 610-21. doi: 10.1016/j.drudis.2010.06.012
- Dietmair S, Timmins NE, Gray PP, Nielsen LK, Kromer JO. Towards quantitative metabolomics of mammalian cells: development of a metabolite extraction protocol. Anal Biochem 2010; 404: 155-64. doi: 10.1016/j. ab.2010.04.031
- Kronthaler J, Gstraunthaler G, Heel C. Optimizing high-throughput metabolomic biomarker screening: a study of quenching solutions to freeze intracellular metabolism in CHO cells. Omics 2012; 16: 90-7. doi: 10.1089/ omi.2011.0048
- Triba MN, Starzec A, Bouchemal N, Guenin E, Perret GY, Le Moyec L. Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells. NMR Biomed 2010; 23: 1009-16. doi: 10.1002/nbm.1516
- Mesti T, Savarin P, Triba MN, Le Moyec L, Ocvirk J, Banissi C, et al. Metabolic impact of anti-angiogenic agents on U87 glioma cells. PLoS One 2014; 9: e99198 doi: 10.1371/journal.pone.0099198
- Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63. org/10.1016/0022-1759(83)90303-4
- Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR 1995; 6: 277-93.
- Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). Journal of Chemometrics 2002; 16: 119-28. doi: 10.1002/cem.695
- Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324: 1029-33. doi: 10.1126/science.1160809
- Billah MM, Anthes JC. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J 1990; 269: 281-91. PMCID: PMC1131573
- Horska A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am 2010; 20: 293-310. doi: 10.1016/j. nic.2010.04.003
- Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro Oncol 2010; 2: 87-95. doi: 10.1093/neu-onc/2.2.87.
- Maurmann L, Belkacemi L, Adams NR, Majmudar PM, Moghaddas S, Bose RN. A novel cisplatin mediated apoptosis pathway is associated with acid sphingomyelinase and FAS proapoptotic protein activation in ovarian cancer Apoptosis 2015; 20: 960-74. doi: 10.1007/s10495-015-1124-2
- Delikatny EJ, Cooper WA, Brammah S, Sathasivam N, Rideout DC. Nuclear magnetic resonance-visible lipids induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res 2002; 62: 1394-400.
- Blankenberg FG, Storrs RW, Naumovski L, Goralski T, Spielman D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood 1996; 87: 1951-6.
- Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, et al. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 1997; 89: 3778-86.
- Al-Saffar NM, Titley JC, Robertson D, Clarke PA, Jackson LE, Leach MO, et al. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br J Cancer 2002; 86: 963-70. doi: 10.1038/sj.bjc.6600188.
- Griffin JL, Lehtimäki KK, Valonen PK, Gröhn OH, Kettunen MI, Ylä-Herttuala S, et al. Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res 2003; 63: 3195-201.
- Opstad KS, Bell BA, Griffiths JR, Howe FA. Taurine: a potential marker of apoptosis in gliomas. Briti J Cancer 2009; 100: 789-94. doi: 10.1038/sj.bjc.6604933
- Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. AJR Am J Roentgenol 1996; 167: 201-9. doi: 10.2214/ajr.167.1.8659372
- Kolpakova ME, Veselkina OS, Vlasov TD. Creatine in cell metabolism and its protective action in cerebral ischemia. Neurosci Behav Physiol 2015; 45: 476-82. doi: 10.1007/s11055-015-0098-4
- Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, et al. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One 2015; 10: e0118781. doi: 10.1371/journal.pone.0118781
- Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, et al. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci USA 2011; 108: 3270-5. doi: 10.1073/pnas.1019393108
- Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010; 70: 859-62. doi: 10.1158/0008-5472. CAN-09-3556
- Halama A, Moller G, Adamski J. Metabolic signatures in apoptotic human cancer cell lines. Omics 2011; 15: 325-35 doi: 10.1089/omi.2010.0121
- Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 2011; 286: 42626-34. doi: 10.1074/jbc. M111.282046
- Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44. doi: 10.1038/nature08617
- DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345-50. doi: 10.1073/pnas.0709747104
- Metallo CM, Walther JL, Stephanopoulos G. Evaluation of 13C isotopic tracers for metabolic flux analysis in mammalian cells. J Biotechnol 2009; 144: 167-74. doi: 10.1016/j.jbiotec.2009.07.010
- Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010; 17: 225-34. doi: 10.1016/j.ccr.2010.01.020